

# WFS1 A134V — Wolframin

Alanine → Valine at position 134. N-terminal cytoplasmic (intrinsically disordered). ClinVar Uncertain significance, AlphaMissense 0.622, DynaMut2  $\Delta\Delta G$  -0.92 kcal/mol (destabilising).

## IDENTITY

Variant	A134V (p.Alanine134Valine)
DNA change	c.401C>T
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV001027526
Amino acid change	Alanine (A) → Valine (V)

## STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 134	<b>90.94</b> HIGH CONFIDENCE
Domain	N-terminal cytoplasmic (intrinsically disordered)
Position context	N-terminal cytoplasmic (intrinsically disordered)
IDR flag	No — pLDDT well above 50 threshold

Position 134 sits in N-terminal cytoplasmic (intrinsically disordered). The wild-type residue is small/hydrophobic (alanine — methyl sidechain); the mutant is small hydrophobic (valine — branched). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

## COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

**0.622**am\_class: **likely pathogenic** —  
threshold > 0.564DYNAMUT2  $\Delta\Delta G$ **-0.92** kcal/molDestabilising · Job  
178092130561

PLDDT (ALPHAFOLD)

**90.94**

high confidence

## CLINICAL EVIDENCE

ClinVar classification	UNCERTAIN SIGNIFICANCE
Review status	criteria provided, multiple submitters, no conflicts
Last evaluated	2025/08/14 00:00
Inheritance	Autosomal dominant pattern indicated by associated DFNA6/14/38 (WFS1 hearing loss 6).
WFS1 variant landscape	A134V is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar) <ul style="list-style-type: none"> <li>• Spastic ataxia</li> <li>• Wolfram syndrome 1</li> <li>• Autosomal dominant nonsyndromic hearing loss 6</li> <li>• Type 2 diabetes mellitus</li> <li>• Wolfram-like syndrome</li> <li>• Cataract 41</li> </ul>

### RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$  + binding site affected → CATEGORY 3 – docking experiments  $\Delta\Delta G 2-4$  → CATEGORY 2 – pharmacological chaperones  $\Delta\Delta G > 4$  → CATEGORY 1 – gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable fold + functional site hit → CATEGORY 4 – site-specific docking

#### Category 3/4 — Most Druggable

$|\Delta\Delta G|=0.92 < 2$  kcal/mol (fold intact) + AlphaMissense 0.622 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Wolframin's fold survives this substitution ( $|\Delta\Delta G|=0.92$  kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.622. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.